281 related articles for article (PubMed ID: 8064160)
1. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
[TBL] [Abstract][Full Text] [Related]
3. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
4. Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.
Itoh H; Nakao K; Mukoyama M; Yamada T; Hosoda K; Shirakami G; Morii N; Sugawara A; Saito Y; Shiono S
J Clin Invest; 1989 Jul; 84(1):145-54. PubMed ID: 2544622
[TBL] [Abstract][Full Text] [Related]
5. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
[TBL] [Abstract][Full Text] [Related]
7. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
[TBL] [Abstract][Full Text] [Related]
8. Role of endogenous atrial natriuretic peptide in DOCA-salt hypertensive rats. Effects of a novel nonpeptide antagonist for atrial natriuretic peptide receptor.
Hirata Y; Matsuoka H; Suzuki E; Hayakawa H; Sugimoto T; Matsuda Y; Morishita Y; Kangawa K; Minamino N; Matsuo H
Circulation; 1993 Feb; 87(2):554-61. PubMed ID: 8381060
[TBL] [Abstract][Full Text] [Related]
9. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Kuro T; Okahara A; Nose M; Ikuse T; Matsumura Y
Biol Pharm Bull; 2000 Jul; 23(7):820-5. PubMed ID: 10919359
[TBL] [Abstract][Full Text] [Related]
10. Altered regulation of renal sodium transporters and natriuretic peptide system in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Regul Pept; 2009 Oct; 157(1-3):76-83. PubMed ID: 19422859
[TBL] [Abstract][Full Text] [Related]
11. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
12. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
13. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection.
Newaz MA; Yousefipour Z; Hercule H; Truong L; Oyekan A
Clin Exp Hypertens; 2003 Aug; 25(6):335-47. PubMed ID: 12940471
[TBL] [Abstract][Full Text] [Related]
14. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Wegner M; Ganten D; Stasch JP
Hypertens Res; 1996 Dec; 19(4):229-38. PubMed ID: 8986453
[TBL] [Abstract][Full Text] [Related]
15. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
Seymour AA; Norman JA; Asaad MM; Fennell SA; Abboa-Offei B; Little DK; Kratunis VJ; Delaney NG; Hunt JT; Di Donato G
J Pharmacol Exp Ther; 1991 Mar; 256(3):1002-9. PubMed ID: 1826031
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
[TBL] [Abstract][Full Text] [Related]
17. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor.
Suzuki E; Hirata Y; Matsuoka H; Sugimoto T; Hayakawa H; Sugimoto T; Kangawa K; Minamino N; Matsuo H
Biochem Biophys Res Commun; 1992 Feb; 182(3):1270-6. PubMed ID: 1531753
[TBL] [Abstract][Full Text] [Related]
18. Blunted pressor responsiveness to quinpirole, a specific dopamine D2 receptor agonist, in conscious deoxycorticosterone acetate/NaCl hypertensive rats is related to atrial natriuretic peptide release.
Chen YF; Jin HK; Paul R; Nagahama S
J Pharmacol Exp Ther; 1988 Aug; 246(2):485-92. PubMed ID: 2969976
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Seymour AA; Asaad MM; Abboa-Offei BE; Rovnyak PL; Fennell S; Rogers WL
J Pharmacol Exp Ther; 1992 Jul; 262(1):60-70. PubMed ID: 1385630
[TBL] [Abstract][Full Text] [Related]
20. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
